| 摘要 |
A subject with symptoms of chronic kidney disease (CKD), who does not have end-stage renal disease (ESRO), can be treated by orally administering a pharmaceutical composition as an active ingredient a therapeutically effective amount of a non-toxic lanthanum compound. In a preferred embodiement, the composition contains lanthanum carbonate hydrate or lanthanum hydroxycarbonate. Administration of a lanthanum compound can prevent the progression of CKD, treat soft tissue calcification, and treat secondary hyperparathyroidism. |
